Drug Trial Radar · NCT05691491
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Sep 28, 2023
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. M1774 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Adding M1774 to temozolomide may shrink or stabilize cancer for longer than temozolomide alone.
Conditions
- Advanced Malignant Solid Neoplasm
- Advanced Microsatellite Stable Colorectal Carcinoma
- Hematopoietic and Lymphatic System Neoplasm
- Metastatic Malignant Solid Neoplasm
- Metastatic Microsatellite Stable Colorectal Carcinoma
- Stage III Colorectal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT scan
Magnetic Resonance ImagingProcedure
Undergo MRI
TemozolomideDrug
Given orally (PO)
TuvusertibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity and the maximum tolerated doseTime frame: Up to 28 days
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Yale University
New Haven, Connecticut
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut
Memorial Hospital East
Shiloh, Illinois
University of Kansas Clinical Research Center
Fairway, Kansas
University of Kansas Cancer Center
Kansas City, Kansas
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri
University of Kansas Cancer Center - North
Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center-South County
St Louis, Missouri
Siteman Cancer Center at Christian Hospital
St Louis, Missouri
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.